Hashimoto's thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis

Otolaryngology - Head and Neck Surgery (United States)

Volumn 148, Issue 3, 2013, Pages 396-402

  Lun, Yu ^a   Wu, Xiaoyu ^a   Xia, Qian ^a   Han, Yanshuo ^a   Zhang, Xiaoyu ^a   Liu, Zhimin ^a   Wang, Fengyi ^a   Duan, Zhiquan ^a   Xin, Shijie ^a   Zhang, Jian ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Hashimoto's thyroiditis; Papillary thyroid cancer; Thyroidstimulating hormone

Indexed keywords

THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; ANTI THYROGLOBULIN; ANTI-THYROGLOBULIN; AUTOANTIBODY; PEROXIDASE;

ADULT; ARTICLE; CANCER PROGNOSIS; CASE CONTROL STUDY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HASHIMOTO DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; THYROID CANCER; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; AUTOIMMUNITY; BLOOD; CANCER STAGING; CARCINOMA; HYPOTHYROIDISM; IMMUNOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAPILLARY CARCINOMA; PATHOLOGY; PROGNOSIS; SEX DIFFERENCE; THYROID TUMOR;

AUTOANTIBODIES; AUTOIMMUNITY; CARCINOMA; CARCINOMA, PAPILLARY; CASE-CONTROL STUDIES; FEMALE; HASHIMOTO DISEASE; HUMANS; HYPOTHYROIDISM; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PEROXIDASE; PROGNOSIS; RISK FACTORS; SEX FACTORS; THYROID NEOPLASMS; THYROTROPIN;

MLCS; MLOWN;

EID: 84876194361     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1177/0194599812472426     Document Type: Article

References (31)

1. Wang Y, Wang W. Increasing incidence of thyroid cancer in Shanghai, China, 1983-2007. Asia Pac J Public Health [published online March 16, 2012].
2. Jung KW, Park S, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat. 2012;44:11-24.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin. 2012;62:10-29.
4. Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasm to Hashimoto disease of the thyroid gland. AMA Arch Surg. 1955;70:291-297.
5. Ahn D, Heo SJ, Park JH, et al. Clinical relationship between Hashimoto's thyroiditis and papillary thyroid cancer. Acta Oncol. 2011;50:1228-1234.
6. Fiore E, Rago T, Latrofa F, et al. Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer. 2011;18: 429-437.
7. Kim KW, Park YJ, Kim EH, et al. Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto's thyroiditis. Head Neck. 2011;33:691-695.
8. Büyükasxik O, Hasdemir AO, Yalcxin E, et al. The association between thyroid malignancy and chronic lymphocytic thyroiditis: should it alter the surgical approach? Endokrynol Pol. 2011;62:303-308.
9. Repplinger D, Bargren A, Zhang YW, Adler JT, Haymart M, Chen H. Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res. 2008;150:49-52.
10. Cipolla C, Sandonato L, Graceffa G, et al. Hashimoto thyroiditis coexistent with papillary thyroid carcinoma. Am Surg. 2005;71:874-878.
11. Zafon C, Obiols G, Baena JA, Castellví J, Dalama B, Mesa J. Preoperative thyrotropin serum concentrations gradually increase from benign thyroid nodules to papillary thyroid microcarcinomas, then to papillary thyroid cancers of larger size. J Thyroid Res. 2012;2012:530721.
12. Fiore E, Rago T, Provenzale MA, et al. Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocr Relat Cancer. 2009;16:1251-1260.
13. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab. 2006;91: 4295-4301. (Pubitemid 44833401)
14. Haymart MR, Glinberg SL, Liu J, Sippel RS, Jaume JC, Chen H. Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol. 2010;71:434-439.
15. Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumour stage. J Clin Endocrinol Metab. 2008;93:809-814. (Pubitemid 351398557)
16. Chinese Anti-Cancer Association. Guidelines for the diagnosis and treatment of differentiated thyroid cancer. Chin J Pract Surg. 2011;31:908-914.
17. Jieping Wu. Huang Jiasi Sugery. Beijing, China: People's Medical Publishing House; 2008.
18. Mukasa K, Noh JY, Kunii Y, et al. Prevalence of malignant tumors and adenomatous lesions detected by ultrasonographic screening in patients with autoimmune thyroid diseases. Thyroid. 2011;21:37-41.
19. Schaller J, Stevenson JK. Development of carcinoma of the thyroid in iodine-deficient mice. Cancer. 1966;19:1063-1080.
20. Fortner JG, George PA, Sternberg SS. Induced and spontaneous thyroid cancer in the Syrian (golden) hamster. Endocrinology. 1960;6:364-376.
21. Farid NR, Shi Y, Zou M. Molecular basis of thyroid cancer. Endocr Rev. 1994;15:202-232. (Pubitemid 24129183)
22. Wynford-Thomas D. Molecular genetics of thyroid cancer. Trends Endocrinol Metab. 1993;4:224-232. (Pubitemid 23293310)
23. Feldt-Rasmussen U. Iodine and cancer. Thyroid. 2001;11:483-486. (Pubitemid 32496288)
24. Franco AT, Malaguarnera R, Refetoff S, et al. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci U S A. 2011;108:1615-1620.
25. Fiore E, Vitti P. Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab. 2012;97:1134-1145.
26. Latrofa F, Ricci D, Vitti P, et al. Characterization of thyroglobulin epitopes in Sardinian adults and juveniles with Hashimoto's thyroiditis: evidence against a major effect of age and genetic background on B-cell epitopes. Clin Endocrinol. 2010;73:110-113.
27. Giordano C, Stassi G, De Maria R, et al. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science. 1997;275:960-963. (Pubitemid 27087708)
28. Bagnasco M, Venuti D, Paolieri F, Torre G, Ferrini S, Canonica GW. Phenotypic and functional analysis at the clonal level of infiltrating T lymphocytes in papillary carcinoma of the thyroid: prevalence of cytolytic T cells with natural killer-like or lymphokine-activated killer activity. J Clin Endocrinol Metab. 1989;69:832-836. (Pubitemid 19245864)
29. Teng W, Shan Z, Teng X, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med. 2006;354:2783-2793. (Pubitemid 43974196)
30. Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009;94:1612-1617.
31. Teng W, Shan Z, Teng X, et al. More than adequate iodine intake may increase subclinical hypothyroidism and autoimmune thyroiditis: a cross-sectional study based on two Chinese communities with different iodine intake levels. Eur J Endocrinol. 2006;164:943-950.